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ABSTRACT. Our aim is to investigate visfatin concentration
and its relationship to glycated hemoglobin (HbA1c), insulin
resistance, lipid parameters, and neonatal birth weight in
women with gestational diabetes mellitus (GDM). In our
study group, there were 47 women with GDM and 31 wom-
en with normal glucose tolerance (NGT) between 33-39
weeks of gestation. Plasma visfatin levels were significant-
ly decreased in pregnant women with GDM compared to
those with NGT (p=0.001). Homeostasis model assessment-
insulin resistance (HOMA-IR) levels were higher in the GDM
group than in the NGT group (p=0.006). In all subjects, plas-
ma visfatin levels were negatively correlated with HOMA-IR,
post-prandial blood glucose, triglycerides, and VLDL choles-
terol (p<0.05). We did not observe any statistically signifi-
cant correlation between the plasma visfatin levels and the
selected parameters in the GDM group, but in the NGT
group plasma visfatin levels were negatively correlated with
HOMA-IR (r=–0.36, p=0.04). There was no correlation be-
tween visfatin concentrations and fetal birth weight in ei-
ther group (p>0.05). By regression analysis, having GDM
was found to be the only significant determinant (t=3.5,
p=0.001) of visfatin concentration (R=0.39, r2=0.15). We
conclude that women with GDM have significantly de-
creased visfatin concentrations in the third trimester. Future
studies are required to establish the exact role of visfatin in
the pathogenesis of GDM. 
(J. Endocrinol. Invest. 31: 610-613, 2008)
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INTRODUCTION
Visfatin, initially considered a pre-B cell colony enhancing
factor, is a novel adipocytokine and is preferentially pro-
duced by visceral fat (1, 2). Visfatin may have a substantial
role in the glucose homeostasis (1, 3). Visfatin concentra-
tions have been reported to be affected by glucose and
insulin in humans (3). There are conflicting studies on visfatin
concentrations in Type 2 diabetes mellitus (DM). Increased
as well as decreased circulating visfatin has been observed
in patients with Type 2 DM (4-6). Therefore, the exact role
of visfatin in Type 2 DM is not fully known. 
Insulin sensitivity decreases by 30-60% in normal preg-
nancy when compared to healthy non-pregnant women
(7). Gestational diabetes mellitus (GDM) is observed in
almost 7% of all pregnancies (8). GDM is characterized
by glucose intolerance, emerging first in pregnancy (9).
Insulin resistance seems to be more apparent with in-
creasing gestational weeks (7). Women with GDM are at
high risk of subsequently developing Type 2 DM (10).
Data available on visfatin levels in patients with GDM are
also controversial. To date, two previous studies (11, 12)
reported increased visfatin concentrations in GDM,
whereas others (13, 14) showed that GDM is associated
with decreased visfatin concentrations.
Since visfatin is an adipocytokine that is associated with
glucose homeostasis, we hypothesized that maternal vis-
fatin concentrations might be altered in pregnant wom-
en with GDM in the third trimester, which is an advanced
state of insulin resistance. Therefore, in the current study,
our main aim is to investigate visfatin levels and their pos-
sible relationship with insulin resistance, lipid parame-
ters, glycated hemoglobin (HbA1c), and neonatal birth
weight in women with GDM in comparison to women
with normal glucose tolerance (NGT). 
MATERIALS AND METHODS
The study was performed with 47 women with GDM [mean age;
30.1±0.6 yr, body mass index (BMI); 29.2±0.5 kg/m2] and 31
women with NGT (mean age; 28.5±0.7 yr, BMI; 28.0±0.6 kg/m2)
between 33-39 weeks of gestation on follow-up at the Depart-
ment of Obstetrics and Gynecology and the Department of
Endocrinology. Screening of a 50-g oral glucose challenge test
(GCT) was performed for all subjects. Women with blood glu-
cose levels above 140 mg/dl at the screening test underwent
an oral glucose tolerance test (OGTT). GDM was diagnosed
when subjects had two or more abnormal values for the OGTT
(normal values are fasting <95, 1-h<180, 2-h<155, and 3-h<140
mg/dl) between 24-28 weeks according to the diagnostic crite-
ria of American Diabetes Association (ADA) (8). The NGT group
was also evaluated with regard to fasting blood glucose (FBG)
levels (below 95 mg/dl) and 1-h post-prandial blood glucose
(PPBG) levels (below 140 mg/dl). The exclusion criteria were de-
fined as any systemic disease known to affect inflammatory mark-
ers, recent infection, high blood pressure and associated dis-
ease (preeclampsia and eclampsia), pregnancies of assisted re-
productive techniques, recent betamethasone use, chronic drug
use (except for vitamins and iron), or multiple pregnancies. None
of the pregnant women were in active labor. Estimation of ges-
tational age was based on routine ultrasonographic screening.
Informed consent was obtained from all participants and the lo-
cal Ethics Committee approved the study. 
Blood samples were collected after an 8-h overnight fast, and
were immediately separated and stored at –80 C until analysis.
Visfatin, FBG, PPBG, insulin, and lipid parameters were deter-
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mined in all subjects between 33-39 weeks. HbA1c was mea-
sured in subjects with GDM. Serum HbA1c levels were measured
by turbidimetric inhibition immunoassay (Roche Diagnostics
GmbH, Mannheim, Germany). Glucose levels were measured
with standard enzymatic methods (Roche Diagnostic GmbH,
Manheim, Germany). Serum concentrations of total cholesterol,
HDL cholesterol (HDL-C), and triglycerides (TG) were measured
using an enzymatic calorimetric method with commercially avail-
able kits (Roche Diagnostic GmbH, Manheim, Germany). VLDL
cholesterol (VLDL-C) levels were calculated as TG/5. LDL choles-
terol levels were calculated using the Friedewald equation.
Plasma visfatin levels were determined with enzyme immunoas-
say [Visfatin C-Terminal (Human) EIA, Phoenix Pharmaceuticals,
Inc, Germany]. The intra-assay and inter-assay coefficients of
variations were below 5% and 14%, respectively. Minimum de-
tectable concentration of visfatin was 2.84 ng/ml. Serum insulin
levels were measured by immunoradiometric assay (sandwich
type assay) using an insulin IRMA kit (Immunotech, Prague,
Czech Republic). The intra-assay and interassay coefficients of
variation for insulin were 4.3% and 3.4%, respectively. The min-
imum detectable concentration of insulin was 0.5 μIU/ml. Insulin
resistance was estimated by using the homeostasis model as-
sessment-insulin resistance (HOMA-IR) index, calculated as
[serum glucose level (mmol/l) x insulin (μIU/ml)]/22.5 (15).
Since only 65 out of 78 women (40 women with GDM and 25
women with NGT) delivered their babies in the studied hospital,
we could only reach the hospital records for these neonates.
Thus, we evaluated and compared plasma visfatin levels with
respect to the birth week and birth weight in both study groups.
Statistical analysis of the study was performed using SPSS version
11.5 for Windows software (Statistical Package for Social Science,
Chicago, IL, USA). Data were expressed as the mean±SEM. To
determine whether or not differences existed between the
groups, a t-test or Mann-Whitney U test was used. p-values be-
low 0.05 were considered statistically significant. For univariate
correlation between continuous variables, Spearman coefficients
were used. In multivariate analysis, we utilized a stepwise re-
gression analysis. Non-normally distributed data were logarith-
mically transformed before analysis.
RESULTS
No statistically significant differences were found be-
tween the GDM group and NGT group with respect to
age, and BMI (p>0.05) in the third trimester. The clinical
and biochemical characteristics of subjects are shown in
Table 1. HOMA-IR levels were higher in the GDM group
(4.9±0.8) than in the NGT group (3.6±0.9) (p=0.006).
Plasma visfatin levels were significantly decreased in
women with GDM compared to those of women with
NGT (75.3±4.9 vs 110.8±7.8 ng/ml, p=0.001). 
In Table 2, we reported the results of Spearman’s corre-
lation test between the plasma visfatin levels with the se-
lected parameters. Plasma visfatin levels were negative-
ly correlated with HOMA-IR, PPBG, TG, and VLDL-C in
all subjects (p<0.05). We did not observe any statistical-
ly significant correlation between the plasma visfatin lev-
els with the selected parameters (such as gestational
week, BMI, FBG, and others) in the GDM group (p>0.05)
as shown in Table 2. But in the NGT group, plasma vis-
fatin levels were negatively correlated with HOMA-IR
(r=–0.36, p=0.04). 
By regression analysis, a model consisting of visfatin as a
dependent variable and GDM/NGT, log HOMA-IR, PP-
BG, log TG, and log VLDL-C as independent variables
was constructed. Based on this, GDM was found to be a
significant determinant (t=3.5, p=0.001) of visfatin con-
centrations (R=0.39, r2=0.15). 
Birth weeks and birth weights were comparable between
the GDM group (no.=40) (38.9±0.2 week, 3379±83 g) and
the NGT group (no.=25) (39.3±0.3 week, 3276±74 g)
(p=0.3 and p=0.4, respectively). There was no correlation
between maternal visfatin concentrations and fetal birth
weight in either group (p>0.05). One in the GDM group
and 2 in the NGT group delivered at preterm. When these
cases were excluded from the statistical analysis, there
were no significant differences with respect to birth week
and birth weight in either group. Furthermore, our find-
ings on correlation analyses between birth weight and
plasma visfatin levels still remained statistically insignifi-
cant in both groups, and in the entire population as well.
Six (12.8%) in the GDM group were treated with insulin in
addition to nutritional therapy and 41 patients (87.2%) in
the GDM group were treated with nutritional therapy
alone. There was no significant difference in visfatin lev-
els between women treated with only nutritional thera-
py (73.3±5.2 ng/ml) or nutritional plus insulin therapy
(88.8±14.8 ng/ml) (p=0.2). 
DISCUSSION
The current study shows that plasma visfatin concentra-
tions were markedly decreased in GDM compared with
NGT in the third trimester of gestation. Contrary to our
findings, Lewandowski et al. (12) found an increase in vis-
fatin levels in 16 patients with GDM at 28 weeks of ges-
tation. They also reported increased visfatin concentra-
tions with worsening of glucose tolerance. Similarly,
with GDM with NGT p
No. 47 31
Age (yr) 30.1±0.6 28.5±0.7 0.08
BMI (kg/m2) 29.2±0.5 28.0±0.6 0.2
Preconceptional 24.9±0.7 23.8±0.8 0.3
BMI (kg/m2)
HOMA-IR 4.9±0.8 3.6±0.9 0.006*
FBG (mg/dl) 81.6±2.9 75.1±1.4 0.2*
PPBG (mg/dl) 126.7±4.5 99.8±3.1 <0.001*
HbA1c (%) 5.5±0.1
TC (mg/dl) 248.0±4.8 251.4±9.4 0.9*
LDL-C (mg/dl) 121.4±6.3 130.8±8.6 0.4*
VLDL-C (mg/dl) 55.2±4.0 46.7±2.6 0.1*
HDL-C(mg/dl) 72.8±2.5 73.8±3.2 0.8*
TG (mg/dl) 276.1±20.2 234.0±13.4 0.1*
Visfatin (ng/ml) 75.3±4.9 110.8±7.8 0.001*
Data are expressed as means±SEM, p>0.05 statistically non-significant,
*with Mann Whitney U test. BMI: body mass index; HOMA-IR: home-
ostasis model assessment-insulin resistance; FBG: fasting blood glucose;
PPBG: post-prandial blood glucose; HbA1c: glycated hemoglobin;  TC: to-
tal cholesterol; LDL-C: LDL cholesterol; VLDL-C: VLDL cholesterol; HDL-
C: HDL cholesterol; TG: triglycerides.
Table 1 - The characteristics of pregnant woman with gestational
diabetes mellitus (GDM) and normal glucose tolerance (NGT).
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Krzyzanowska et al. (11) investigated visfatin concentra-
tions in women with GDM between 28-30 and 38-40
weeks of gestation and after delivery. Authors reported
that women with GDM had increased concentrations of
visfatin compared to healthy pregnant controls. On the
other hand, studies by Chan et al. (13) and Haider et al.
(14) revealed decreased visfatin concentrations in patients
with GDM. Chan et al. (13) measured visfatin levels in 20
women with GDM at 24 to 28 weeks of gestation and
found that plasma visfatin concentrations were signifi-
cantly lower in GDM than those in healthy pregnant wom-
en. In agreement with this study, Haider et al. (14) re-
ported recently that women with GDM at 24-28 weeks
of gestation had low fasting plasma visfatin and sup-
pressed visfatin response when compared to women with
NGT during OGTT. The results on this particular study
are somehow conflicting. The underlying reason may be
associated with the largely unknown metabolism of vis-
fatin. Besides, which factors exactly influence circulating
visfatin concentrations in GDM have not been established
yet. Nevertheless, present data regarding visfatin levels
in Type 2 DM and obesity are also controversial. Previous
studies (4, 5) reported increased circulating visfatin in pa-
tients with Type 2 DM, whereas another study (6) found
that Type 2 diabetic patients showed decreased plasma
visfatin concentrations. Circulating visfatin levels are re-
duced after weight loss in obese subjects (16), yet, in con-
trast, another study (17) found that weight loss has an in-
creasing effect on visfatin concentrations.
As far as we know, there is no published study with re-
spect to the changes in placental visfatin expression and
the relationship of visfatin to insulin resistance in GDM. A
possible reason for decreased maternal visfatin in wom-
en with GDM in our study might be associated with some
unknown factors that can lower the secretion of visfatin
from placenta and fetal membranes of diabetic pregnant
women. For example, placental visfatin expression in nor-
mal pregnancy has been shown in a previous study (18).
Malamitsi-Puchner et al. (19) suggested that placental ex-
pression and transfer of visfatin could be responsible for
intrauterine visfatin concentrations in normal full-term
pregnancies, as well. The correlation between maternal
and fetal visfatin levels in intrauterine growth-restricted
and normal pregnancies was found in a different study
by the same group (20). This supports the idea of
transplacental transport of visfatin. Therefore, placental
visfatin expression should be investigated in GDM. 
Furthermore, visfatin concentrations might be under the
effects of some hormones (including human placental lac-
togen and progesterone) that circulate in high concen-
trations during pregnancy (21), although the effect of
these hormones on circulating visfatin in GDM is not cur-
rently known. On the other hand, it may be speculated
that insulin therapy could effect our results since insulin
administration was shown to decrease visfatin concentra-
tions (14). However, this effect is unlikely because our pa-
tients were mainly treated with nutritional therapy alone.
Another key point may be related with the changes in vis-
ceral fat tissue in GDM since plasma visfatin levels were
found to be increased in proportion to visceral fat accu-
mulation (2). Changes in regional fat distribution and in-
creased intra-abdominal visceral fat accumulation have
been reported during normal pregnancy (22). Post-par-
tum visceral fat was found to be greater in patients with
previous GDM who also had current impaired glucose tol-
erance (23). However, to the best of our knowledge, there
is not enough evidence about changes in visceral fat com-
position in pregnant women with GDM. If there is an in-
crease in visceral fat accumulation in patients with GDM,
decreased visfatin may be a defensive mechanism in these
patients. Taken together, further studies are needed to
reveal the unknown mechanisms associated with alter-
ations in visfatin concentrations in patients with GDM. 
In the current study, although visfatin levels have been
negatively correlated with insulin resistance in all subjects,
we observed that there was a significant negative correla-
tion between visfatin and HOMA-IR in the NGT group,
whereas a similar correlation did not exist in the GDM
group. Pregnancy is a state that creates variable degrees
of insulin resistance and our results suggest that visfatin is
associated with the degree of insulin resistance in normal
pregnant women, but not in women with GDM. In a study
performed in non-diabetic pregnant women, maternal vis-
fatin levels in the first trimester were found to predict sec-
ond trimester insulin sensitivity (24). On the other hand,
some previous studies reported that pregnant women with
intrauterine growth retardation had increased maternal vis-
fatin levels compared to controls (20, 25). Post-natal first
day fetal fasting insulin was observed to be decreased in
the study by Malamitsi-Puchner et al. (20). Interestingly,
our results showing that women with GDM had decreased
visfatin levels suggest this kind of relationship between fe-
tal insulin level and maternal visfatin since fetuses from
women with GDM were expected to be hyperinsulinemic.
However, we could not measure fetal visfatin and insulin
levels in our study. Therefore, the association of maternal
visfatin with the degree of fetal insulin sensitivity or resis-
tance deserves further investigation.
Table 2 - Spearman’s correlation coefficients of plasma visfatin
levels with selected variables in pregnant woman with gestational
diabetes mellitus (GDM) and normal glucose tolerance (NGT).
All groups with GDM with NGT
r p r p r p
Age  (yr) –0.11 0.3 –0.13 0.3 0.08 0.6
Gestational week 0.16 0.1 0.07 0.6 –0.008 0.9
BMI (kg/m2) 0.03 0.7 0.07 0.6 0.21 0.2
Preconceptional 0.01 0.9 0.1 0.4 –0.04 0.9
BMI (kg/m2)
HOMA-IR –0.30 0.008 –0.1 0.4 –0.36 0.04
FBG (mg/dl) –0.20 0.07 –0.2 0.16 –0.10 0.5
PPBG (mg/dl) –0.27 0.01 –0.1 0.37 0.09 0.5
HbA1c (%) –0.1 0.38
TC (mg/dl) –0.09 0.4 –0.1 0.3 –0.04 0.7
LDL-C (mg/dl) 0.06 0.5 0.07 0.6 –0.03 0.8
VLDL-C (mg/dl) –0.23 0.03 –0.2 0.08 –0.02 0.8
HDL-C (mg/dl) 0.10 0.3 0.1 0.3 0.005 0.9
TG (mg/dl) –0.22 0.04 –0.2 0.09 –0.01 0.9
Birth weight (g) –0.15 0.2 –0.02 0.8 –0.30 0.1
BMI: body mass index; HOMA-IR: homeostasis assessment-insulin resis-
tance; FBG: fasting blood glucose; PPBG: post-prandial blood glucose;
HbA1c: glycated hemoglobin; TC: total cholesterol; LDL-C: LDL choles-
terol; VLDL-C: VLDL cholesterol; HDL-C: HDL cholesterol; TG: triglycerides.
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Visfatin concentrations have been reported to be nega-
tively correlated with HOMA-IR and TG in a study cover-
ing the relatives of the patients with familial hyperlipi-
demia and non-diabetic subjects (26). In the current
study, we also found that plasma visfatin levels were neg-
atively correlated with TG and VLDL-C in all subjects. Yet,
we did not observe such a relationship in a multiple re-
gression analysis, except for GDM. 
Previous studies revealed that maternal adipocytokines
have considerable effects on neonatal birth weight (27).
A positive relationship between neonatal visfatin and
birth weight was shown in normal pregnancies (19, 28).
In the current study, we found no association between
third trimester maternal visfatin concentrations and
birth weight. 
The results of the present study indicate that women with
GDM had significantly decreased visfatin concentrations
in the third trimester. Furthermore, maternal visfatin lev-
els at the third trimester are not a determinant of fetal
birth weight. Future studies are required to establish the
exact role of visfatin in the pathogenesis of GDM. 
